Cynosure Launches TempSure Vitalia for Feminine Wellness

Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to internal and external vaginal tissue to improve local circulation.

The TempSure™ Vitalia treatment, administered using a probe specifically designed for women's genitalia, delivers precise heating for smaller, hard-to-reach areas such as vaginal and labial tissue, without hormones or the need for invasive procedures. Treatments can last between 15 and 30 minutes, depending on the treatment area, and there's no downtime once the procedure is complete.

Unlike other radiofrequency devices, TempSure™ Vitalia has the distinct advantage of Therapeutic Logic Control (TLC) – a revolutionary time and temperature monitoring system that ensures treatment timing will begin only when the target tissue is at therapeutic temperature, helping deliver repeatable treatment results procedure after procedure. The device also has a unique dose counter that monitors and effectively delivers the recommended dose of radiofrequency energy to the target area.

"TempSure Vitalia responds to customers who expressed a need for a consistent and effective intimate wellness therapy that takes the guesswork out of radiofrequency treatments," said Kevin Thornal, Hologic's Division President, Cynosure. "It also expands the offerings on our TempSure radiofrequency platform. We are pleased that in just six months, we were able to launch an additional handpiece while simultaneously providing a solution to patients who have experienced changes in their vaginal health over time."

In January 2018, Cynosure launched the TempSure™ platform with TempSure™ Envi, a device for minimizing fine facial lines and wrinkles, tightening the skin through soft tissue coagulation, and improving the appearance of cellulite.